These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25270118)

  • 1. Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients.
    Pacheco-Velázquez SC; Gallardo-Pérez JC; Aguilar-Ponce JL; Villarreal P; Ruiz-Godoy L; Pérez-Sánchez M; Marín-Hernández A; Ruiz-García E; Meneses-García A; Moreno-Sánchez R; Rodríguez-Enríquez S
    Int J Oncol; 2014 Dec; 45(6):2549-59. PubMed ID: 25270118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.
    Hartog H; Horlings HM; van der Vegt B; Kreike B; Ajouaou A; van de Vijver MJ; Marike Boezen H; de Bock GH; van der Graaf WT; Wesseling J
    Breast Cancer Res Treat; 2011 Oct; 129(3):725-36. PubMed ID: 21107683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer.
    Gorshein E; Klein P; Boolbol SK; Shao T
    Clin Breast Cancer; 2014 Oct; 14(5):309-14. PubMed ID: 24703318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.
    Koo JS; Jung W
    Pathobiology; 2010; 77(6):289-300. PubMed ID: 21266827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
    Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
    Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
    Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
    Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced risk of axillary lymphatic spread in triple-negative breast cancer.
    Holm-Rasmussen EV; Jensen MB; Balslev E; Kroman N; Tvedskov TF
    Breast Cancer Res Treat; 2015 Jan; 149(1):229-36. PubMed ID: 25488719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc.
    Cui J; Jiang H
    Medicine (Baltimore); 2019 Oct; 98(40):e17370. PubMed ID: 31577739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
    Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
    Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.
    Yamamoto Y; Ibusuki M; Okumura Y; Kawasoe T; Kai K; Iyama K; Iwase H
    Breast Cancer Res Treat; 2008 Aug; 110(3):465-75. PubMed ID: 17805961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of tumor subtypes in male breast cancer: a population-based study.
    Leone JP; Leone J; Zwenger AO; Iturbe J; Vallejo CT; Leone BA
    Breast Cancer Res Treat; 2015 Aug; 152(3):601-9. PubMed ID: 26126972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
    Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
    Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cadherins E and P expression in the molecular types of breast cancer].
    Fernández Á; Reigosa A; Caleiras E; Saldivia F; Hardisson D; Sanz F
    Invest Clin; 2015 Jun; 56(2):155-68. PubMed ID: 26299056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.
    Nair R; Roden DL; Teo WS; McFarland A; Junankar S; Ye S; Nguyen A; Yang J; Nikolic I; Hui M; Morey A; Shah J; Pfefferle AD; Usary J; Selinger C; Baker LA; Armstrong N; Cowley MJ; Naylor MJ; Ormandy CJ; Lakhani SR; Herschkowitz JI; Perou CM; Kaplan W; O'Toole SA; Swarbrick A
    Oncogene; 2014 Jul; 33(30):3992-4002. PubMed ID: 24056965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
    Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
    Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
    J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.